First-pass extracted concept

adeno-associated viruses

Candidate: concept label2 source documents3 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

AAVs, AAV vectors

Extracted Explainers

What the tool is doing

Presented as a highlighted delivery modality within the editorial's vector-based cancer immunotherapy theme.

Source 2DOI PubMed

Evidence Snippets

We additionally prepared OPO loaded with adeno-associated viruses (AAVs) and demonstrated that AAV titre is homogeneously distributed throughout the material, is stable for up to 3 days, and that AAVs administered in OPO are able to transduce ARPE-19 cells.

Evidence 1Source 1DOI PubMedprovenance

The editorial explicitly points to five topic contributions and highlights several concrete subthemes: oncolytic viruses, adenoviral and AAV delivery, nanoparticle-enabled combination immunotherapy, and translation from preclinical models to patients.

Evidence 2Source 2DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 2 linked claims Claim 1 Claim 2

Source 2primary paper2025MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Linked Claims

Claim 1application demosupports2026Source 1DOI PubMed

AAVs administered in OPO are able to transduce ARPE-19 cells.

Claim 2cargo compatibilitysupports2026Source 1DOI PubMed

AAVs loaded in OPO are homogeneously distributed throughout the material and remain stable for up to 3 days.

Claim 3scope summarysupports2025Source 2DOI PubMed

This editorial summarizes a research topic on vector-based gene delivery in cancer immunotherapy and highlights oncolytic viruses, adenoviral delivery, AAV delivery, nanoparticle-enabled combination immunotherapy, and translation from preclinical models to patients as concrete subthemes.